Zevra reports Q2 2026 results as MIPLYFFA revenue grows and EU review continuesAug 5Quarterly updatearimoclomolZevra Therapeutics, Inc.
Zevra Therapeutics posts results for Phase 2 SDX trial in idiopathic hypersomniaJun 30Trial updateserdexmethylphenidateZevra Therapeutics, Inc.
Sign inSign in